• icon

    Pol. Ind. Noain-Esquiroz, C/S, Nave 4

  • icon
    Phone us


    633 674 251

  • icon
    Contact us



The first Probiotic supplement
for prediabetic people

About us

About Us

Welcome To Genbioma

Specialized in research and development services to develop new solutions in the field of probiotics and other bioactive compounds with demonstrated properties for human health.

Our mission is to contribute to the improvement of human health by utilizing our talents and capabilities for probiotics and bioactive compounds research and development. Dietary supplement industries and food industry are our main partners. Our first goal is to leverage the central role of probiotics and the gut microbiota on the glycemic regulation in prediabetes. Our lead Project is a dietary supplement designed by using specific strains selected for its potential ability for long-term glycemic regulation that aims at offering a complementary strategy to people in early stages of diabetes.

Genbioma was founded in 2019 thanks to the industrial know-how derived from microorganisms obtained from probiotic animal feed research and the preclinical research on animal health, to deepen and improve the R&D on own probiotics for food applications in human health.

Genbioma works closely with partners to cover every research, development and market challenges. We have forged alliances and collaborative relationships with public and private partners, which include universities, industry, and world-renowned research centres.

Besides the scientific and industrial founder team, the company is integrated by a multi-skilled team involving private investors (Clave Capital), strategic partners from the pharmacy sector (CINFA) and animal health and nutrition (Pentabiol S.L.) and supported in a research agreement with the Centre for Nutrition Research - University of Navarra.

Behind GENBIOMA, stands a team of health experts deeply dedicated to do research and development on probiotic bacteria for food applications on human health. We are scientists from the fields of biology, biochemistry, biotechnology, and food technology.

Our aim on Consumer Health Care and our conviction that probiotics and bioactive compounds are the future of health benefit have brought us to the development of new food products on the market.

Our Company is an innovative biological technology platform for creating innovative products for specific human health targets. The core expertise is finding, designing and developing microorganisms and food applications for industrial and health-related purposes.

Through investment in R&D to develop probiotics & bioactive compounds and new solutions in the field of nutraceutical and functional food products focus on health Genbioma aims to become a reference in its market, with an international vocation. We are in close contact with our clients to design and adapt our products to their needs and specifications.
- Company founded in June
- First project focus on own probiotics R&D
- Clave Capital 1st financing round
- Strategic partnership with CINFA and with the Centre for Nutrition Research of University of Navarra
- First Genbioma EU patent of our strain collection

2020 - University of Navarra as a Shareholder




Univ. de Navarra

Visitar web


Visitar web

Clave Capital

Visitar web


Visitar web

B2B. Business to Business.

Different ways to partnership with the goal to cover your specific needs. We are a B2B provider for Dietary Supplements & Food Industry.
If you want to become one of our partners, please contact us.


(+34)633 674 251


Our product

Genbioma, proven effectiveness of probiotics for glycemia regulation.
Genbioma develops its own probiotic supplements based on objective measurable criteria which are the result of research and/or trials on:

  • Our probiotic strains collection backed by scientific data
  • Scientifically documented and patented probiotic strains
  • Pre-clinical and clinical evaluation
  • Ready-to-go probiotic food supplement for regulating blood glucose level
  • Probiotics for the target population: prediabetic status and other related areas of use
  • Viability and stability probiotics over time and so as to guarantee an optimum food supplement
  • Probiotics for dietary supplements ready for the market
  • Intellectual property protection & Regulatory support

We're developing the first Probiotic supplement for prediabetic people.



Genbioma is a research platform for probiotic and bioactive compounds studies, focused on understanding its potential to improve or maintain health in target populations.

The research includes the selection, identification, scale-up and production of our patented strain collection, in vitro and in vivo pre-clinical studies in animal models as well as clinical trials in humans, to evaluate food safety and health benefits of probiotics and other bioactive compounds for specific health purposes.

Clinical trials (mainly nutritional intervention trials to prediabetic population) performed in collaboration with prestigious research centres to further develop and extend the clinical documentation and probiotic applications.
The company has one patent pending approval to protect our company intellectual property.

get in touch

Contact us